康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00867 康哲药业

未开盘 02-04 16:08:25

14.580

+0.100

+0.69%

最高14.780	最低14.280	成交量305.82万
今开14.450	昨收14.480	日振幅3.45%
总市值355.75亿	流通市值355.68亿	总股本24.40亿
成交额4,449万	换手率0.13%	流通股本24.40亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00867","market":"HK","secType":"STK","nameCN":"康哲药业","latestPrice":14.58,"timestamp":1770192505002,"preClose":14.48,"halted":0,"volume":3058199,"delay":0,"changeRate":0.006906077348066274,"floatShares":2439528512,"shares":2440000000,"eps":0.667298,"marketStatus":"未开盘","change":0.1,"latestTime":"02-04 16:08:25","open":14.45,"high":14.78,"low":14.28,"amount":44488583,"amplitude":0.03453,"askPrice":14.58,"askSize":23000,"bidPrice":14.56,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":0.748149,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770255000000},"marketStatusCode":0,"adr":0,"listingDate":1285603200000,"exchange":"SEHK","adjPreClose":14.48,"dividendRate":0.020997,"openAndCloseTimeList":[[1770168600000,1770177600000],[1770181200000,1770192000000]],"volumeRatio":0.497288,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00867","defaultTab":"news","newsList":[{"id":"2608135488","title":"每日卖空追踪 | 康哲药业 02月04日卖空量成交39.5万股，卖空比例为14.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608135488","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608135488?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:30","pubTimestamp":1770193816,"startTime":"0","endTime":"0","summary":"康哲药业北京时间02月04日，涨0.69%，卖空量成交39.5万股，较上一交易日减少78.89%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163317a47b0b76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163317a47b0b76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BVYPNP33.GBP","SG9999015986.USD","SG9999015952.SGD","IE00BMCWC346.EUR","BK1593","IE00BYV24P56.USD","SG9999004220.SGD","IE00BVYPNQ40.USD","SG9999015978.USD","LU2488822045.USD","00867","SG9999015945.SGD","BK1191","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"2608351002","title":"康哲药业02月04日获主力加仓11.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608351002","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608351002?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:16","pubTimestamp":1770192961,"startTime":"0","endTime":"0","summary":"02月04日, 康哲药业股价涨0.69%，报收14.58元，成交金额4448.9万元，换手率0.13%，振幅3.45%，量比0.50。康哲药业今日主力资金净流入11.2万元，连续3日净流入，上一交易日主力净流入151.1万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为52.17%，平均涨幅为2.52%。该股近5个交易日上涨4.73%，主力资金累计净流入1508.8万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2356.0万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204162327a6d1f668&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204162327a6d1f668&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015945.SGD","IE00BVYPNP33.GBP","SG9999004220.SGD","SG9999015986.USD","SG9999015952.SGD","BK1593","00867","LU2488822045.USD","IE00BMCWC346.EUR","BK1191","IE00BGHQDM52.EUR","SG9999015978.USD","IE00BYV24P56.USD","IE00BVYPNQ40.USD"],"gpt_icon":0},{"id":"1149237753","title":"康哲药业创新药CMS-D017获慢性肾病适应症临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1149237753","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149237753?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:02","pubTimestamp":1770123727,"startTime":"0","endTime":"0","summary":"康哲药业宣布，其自主研发的创新药物CMS-D017针对慢性肾病适应症的临床试验已获得监管机构批准。该进展标志着公司在肾病治疗领域的研发取得重要突破，为后续临床研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BMCWC346.EUR","SG9999015986.USD","IE00BVYPNP33.GBP","SG9999015978.USD","BK1593","LU2488822045.USD","00867","IE00BVYPNQ40.USD","SG9999015945.SGD","SG9999015952.SGD","BK1191","IE00BGHQDM52.EUR","IE00BYV24P56.USD","SG9999004220.SGD"],"gpt_icon":0},{"id":"2608795048","title":"康哲药业(00867)自主研发的创新药CMS-D017胶囊获得补体参与介导的肾脏疾病适应症药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608795048","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608795048?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:01","pubTimestamp":1770123674,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布，于2026年2月3日，集团自主研发的创新药CMS-D017胶囊获得中国国家药品监督管理局签发的药物临床试验批准通知书。CMS-D017通过靶向抑制补体因子B，阻止补体旁路途径的异常活化，减低膜攻击复合物对靶组织和器官的损伤，缓解补体失调相关疾病的进展。此前，CMS-D017拟用于治疗阵发性睡眠性血红蛋白尿症，已于2026年1月30日获得药物临床试验批准通知书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","SG9999015978.USD","159992","BK1161","06978","LU2488822045.USD","LU0553294199.USD","LU0949170772.SGD","LU2346227817.USD","IE00BVYPNQ40.USD","BK4208","SG9999015986.USD","00867","LU1894683264.USD","SG9999004220.SGD","BK1593","IE00BYV24P56.USD","BK4585","IE00BGHQDM52.EUR","BK1191","LU0545039389.USD","LU1894683348.USD","LU1003077747.HKD","SG9999015952.SGD","IE00BVYPNP33.GBP","SG9999015945.SGD","BK1574","LU2637428348.USD","LU2500361329.USD","LU0661504455.SGD","LU0738911758.USD","CMS","IE00BMCWC346.EUR"],"gpt_icon":0},{"id":"2608750848","title":"研报掘金丨中金：上调康哲药业目标价至16.5港元，维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2608750848","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608750848?lang=zh_cn&edition=full","pubTime":"2026-02-03 11:07","pubTimestamp":1770088022,"startTime":"0","endTime":"0","summary":"中金发表报告指，康哲药业旗下德镁医药已于1月30日获得国家药品监督管理局批准磷酸芦可替尼乳膏(白癜风适应症)新药上市许可申请。该行维持公司2025年盈利预测为17.4亿元，基于新产品带来的增量收入，将2026年盈利预测上调5%至19.8亿元，并新增2027年盈利预测为24.2亿元。该行维持对康哲药业的“跑赢行业”评级，目标价上调7%至16.5港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260203/31993948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["00867"],"gpt_icon":0},{"id":"1100829203","title":"康哲药业（00867）公布2026年1月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1100829203","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100829203?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:47","pubTimestamp":1770025622,"startTime":"0","endTime":"0","summary":"2026年2月2日，康哲药业控股有限公司（下称“康哲药业”，股票代码：00867）披露2026年1月股份变动月报。报告期为2026年1月1日至2026年1月31日。\n本月公司注册股本维持在20,000,000,000股普通股，每股面值为0.005美元，注册股本总额为1亿美元。截至1月底，已发行股份总数为2,439,528,512股，且无库藏股；与上月底相比，本期并无新增发行或购回注销活动。\n康哲药业确认，截至2026年1月31日，公司已符合香港联交所有关上市规则规定的最低公众持股量，并遵守了所有适用监管要求。本次月报由公司秘书吴三燕签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"gpt_icon":0},{"id":"2608889638","title":"每日卖空追踪 | 康哲药业 02月02日卖空量成交115.3万股，卖空比例为12.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889638","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608889638?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:30","pubTimestamp":1770021016,"startTime":"0","endTime":"0","summary":"康哲药业北京时间02月02日，涨7.77%，卖空量成交115.3万股，较上一交易日减少29.87%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163251a6c981ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163251a6c981ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015978.USD","SG9999015952.SGD","IE00BMCWC346.EUR","BK1191","SG9999004220.SGD","LU2488822045.USD","IE00BVYPNQ40.USD","SG9999015986.USD","00867","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","SG9999015945.SGD","IE00BYV24P56.USD","BK1593"],"gpt_icon":0},{"id":"2608968038","title":"康哲药业02月02日主力净流入1613.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2608968038","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608968038?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:15","pubTimestamp":1770020128,"startTime":"0","endTime":"0","summary":"02月02日, 康哲药业股价涨7.77%，报收15.12元，成交金额1.5亿元，换手率0.41%，振幅10.48%，量比2.45。康哲药业今日主力资金净流入1613.4万元，上一交易日主力净流出329.4万元。该股近5个交易日上涨10.42%，主力资金累计净流入1372.4万元；近20日主力资金累计净流入2470.4万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202161737a6c9712b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202161737a6c9712b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BVYPNP33.GBP","IE00BVYPNQ40.USD","SG9999015945.SGD","BK1191","LU2488822045.USD","BK1593","SG9999015978.USD","00867","IE00BGHQDM52.EUR","SG9999015986.USD","IE00BMCWC346.EUR","SG9999004220.SGD","IE00BYV24P56.USD","SG9999015952.SGD"],"gpt_icon":0},{"id":"1158281149","title":"康哲药业盘中涨超6%！机构指芦可替尼乳膏国内获批有望填补白癜风靶向治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=1158281149","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158281149?lang=zh_cn&edition=full","pubTime":"2026-02-02 10:35","pubTimestamp":1769999717,"startTime":"0","endTime":"0","summary":"2月2日，$康哲药业$盘中涨超6%，机构指芦可替尼乳膏国内获批有望填补白癜风靶向治疗空白。根据公告公司估算，中国约1030万人患有白癜风，现有TCS/TCIs治疗存在临床缺陷，长期用药具有不良反应或疗效有限，该行认为芦可替尼乳膏国内获批有望填补白癜风靶向治疗空白，满足临床未被满足需求。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"aeca22c37fda52bbfcfcdb537e07bc7f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","SG9999004220.SGD","00867","IE00BVYPNP33.GBP","IE00BMCWC346.EUR","IE00BYV24P56.USD","LU2488822045.USD","IE00BVYPNQ40.USD","SG9999015986.USD","SG9999015978.USD","IE00BGHQDM52.EUR","SG9999015952.SGD","SG9999015945.SGD","BK1191"],"gpt_icon":1},{"id":"2608202833","title":"港股异动 | 康哲药业(00867)涨超3% 机构指芦可替尼乳膏国内获批有望填补白癜风靶向治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2608202833","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608202833?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:55","pubTimestamp":1769997353,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康哲药业涨超3%，截至发稿，涨3.14%，报14.47港元，成交1838.61万港元。产品用于治疗12岁及以上儿童和成人患者伴面部受累的非节段型白癜风，是中国批准的首款且唯一用于白癜风治疗的靶向药，满足巨大未被满足的临床需求。根据公告公司估算，中国约1030万人患有白癜风，现有TCS/TCIs治疗存在临床缺陷，长期用药具有不良反应或疗效有限，该行认为芦可替尼乳膏国内获批有望填补白癜风靶向治疗空白，满足临床未被满足需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"aeca22c37fda52bbfcfcdb537e07bc7f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015952.SGD","BK4585","IE00BYV24P56.USD","BK4588","BK1593","SG9999015978.USD","LU2488822045.USD","SG9999004220.SGD","IE00BMCWC346.EUR","SG9999015945.SGD","IE00BVYPNQ40.USD","BK1191","00867","SG9999015986.USD","IE00BVYPNP33.GBP","VT","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"2608838433","title":"中金：维持康哲药业(00867)“跑赢行业”评级 目标价升至16.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608838433","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608838433?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:22","pubTimestamp":1769995377,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持康哲药业“跑赢行业”评级，考虑板块中枢上行上调目标价7%至16.50港元。该行维持25年盈利预测17.35亿元，考虑新品上市带来收入增量上调26年盈利预测5%至19.84亿元，引入27年盈利预测24.18亿元。公司公告旗下德镁医药的磷酸芦可替尼乳膏已于2026年1月30日经NMPA获批上市，用于治疗12岁及以上儿童和成人患者伴面部受累的非节段型白癜风。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00867"],"gpt_icon":0},{"id":"1138394829","title":"康哲药业创新药补体因子B抑制剂CMS-D017获PNH临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=1138394829","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138394829?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:28","pubTimestamp":1769772493,"startTime":"0","endTime":"0","summary":"康哲药业宣布，其自主研发的创新药补体因子B抑制剂CMS-D017已获得临床试验批准，适应症为阵发性睡眠性血红蛋白尿症（PNH）。此次获批标志着该药物正式进入临床开发阶段，有望为PNH患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","BK1191","00867","IE00BVYPNP33.GBP","BK1593","SG9999015978.USD","IE00BMCWC346.EUR","IE00BVYPNQ40.USD","LU2488822045.USD","SG9999015945.SGD","SG9999015952.SGD","IE00BGHQDM52.EUR","IE00BYV24P56.USD","SG9999015986.USD"],"gpt_icon":0},{"id":"2607014721","title":"康哲药业(00867)：创新药补体因子B抑制剂CMS-D017 获得阵发性睡眠性血红蛋白尿症适应症药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2607014721","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607014721?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:25","pubTimestamp":1769772345,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布，于2026年1月30日，集团自主研发的创新药CMS-D017胶囊获得中国国家药品监督管理局签发的药物临床试验批准通知书。NMPA同意集团在中国健康参与者中开展评价CMS-D017安全性、耐受性、药代动力学和药效动力学特征的临床试验。CMS-D017是一种新型选择性补体因子B小分子抑制剂。CMS-D017在临床前研究中表现出优异的有效性和安全性，临床拟用于治疗阵发性睡眠性血红蛋白尿症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06978","SG9999015978.USD","LU0553294199.USD","00867","SG9999015945.SGD","BK1593","LU2488822045.USD","LU0949170772.SGD","SG9999015986.USD","159992","CMS","IE00BMCWC346.EUR","BK4208","SG9999004220.SGD","BK1191","LU2346227817.USD","LU0661504455.SGD","IE00BVYPNQ40.USD","LU1894683348.USD","LU2500361329.USD","BK4585","IE00BGHQDM52.EUR","LU2637428348.USD","BK1574","LU1003077747.HKD","SG9999015952.SGD","BK4588","IE00BYV24P56.USD","LU0545039389.USD","LU1894683264.USD","LU0738911758.USD","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"2607073280","title":"每日卖空追踪 | 康哲药业 01月30日卖空量成交33.6万股，卖空比例为4.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607073280","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607073280?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:30","pubTimestamp":1769761817,"startTime":"0","endTime":"0","summary":"康哲药业北京时间01月30日，涨0.5%，卖空量成交33.6万股，较上一交易日减少18.84%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130163623a468514e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130163623a468514e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00867","LU2488822045.USD","SG9999015945.SGD","IE00BVYPNQ40.USD","BK1191","SG9999015978.USD","SG9999004220.SGD","SG9999015952.SGD","SG9999015986.USD","IE00BVYPNP33.GBP","IE00BMCWC346.EUR","BK1593","IE00BGHQDM52.EUR","IE00BYV24P56.USD"],"gpt_icon":0},{"id":"2607610067","title":"康哲药业(00867)：创新药磷酸芦可替尼乳膏中国上市许可申请获批为中国批准的首款且唯一用于白癜风治疗的靶向药","url":"https://stock-news.laohu8.com/highlight/detail?id=2607610067","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607610067?lang=zh_cn&edition=full","pubTime":"2026-01-30 12:14","pubTimestamp":1769746492,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业(00867)发布公告，旗下德镁医药有限公司(“德镁医药”，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，)已于2026年1月30日获得中国国家药品监督管理局(NMPA)批准磷酸芦可替尼乳膏(白癜风适应症)新药上市许可申请(NDA)。产品用于治疗12岁及以上儿童和成人患者伴面部受累的非节段型白癜风，是中国批准的首款且唯一用于白癜风治疗的靶向药，满足巨大未被满足的临床需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BYV24P56.USD","IE00BMCWC346.EUR","LU2488822045.USD","IE00BVYPNQ40.USD","SG9999004220.SGD","BK1593","SG9999015986.USD","IE00BGHQDM52.EUR","SG9999015978.USD","BK1574","SG9999015945.SGD","BK1161","06978","00867","SG9999015952.SGD","IE00BVYPNP33.GBP","BK1191","159992"],"gpt_icon":0},{"id":"1105366304","title":"康哲药业磷酸鲁索替尼乳膏新药申请在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1105366304","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105366304?lang=zh_cn&edition=full","pubTime":"2026-01-30 12:09","pubTimestamp":1769746151,"startTime":"0","endTime":"0","summary":"康哲药业宣布，其磷酸鲁索替尼乳膏的新药上市申请已获得中国监管部门的批准。这一进展标志着该药物正式获准在中国市场销售和使用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","IE00BMCWC346.EUR","LU2488822045.USD","SG9999015978.USD","IE00BVYPNP33.GBP","SG9999004220.SGD","SG9999015952.SGD","IE00BVYPNQ40.USD","IE00BGHQDM52.EUR","SG9999015986.USD","BK1191","00867","SG9999015945.SGD","IE00BYV24P56.USD"],"gpt_icon":0},{"id":"2607806521","title":"成都先导与康哲药业达成合作 DEL及HAILO平台赋能多靶点创新药开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2607806521","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607806521?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:13","pubTimestamp":1769735597,"startTime":"0","endTime":"0","summary":"人民财讯1月30日电，据成都先导消息，近日，成都先导与康哲药业控股有限公司（简称“康哲药业”）附属公司签署合作协议，成都先导将为康哲药业针对多个特定靶点的创新药物提供开发服务。成都先导将依托DNA编码化合物库（DEL）技术平台及高通量AI驱动分子优化平台HAILO，为康哲药业提供从靶点验证到临床前候选化合物（PCC）的一站式开发服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303636273434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BVYPNQ40.USD","SG9999015986.USD","SG9999015945.SGD","IE00BYV24P56.USD","IE00BMCWC346.EUR","SG9999015978.USD","LU2488822045.USD","BK1593","06978","BK1161","BK1574","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","SG9999004220.SGD","BK1191","SG9999015952.SGD","688222","00867","BK0216","159992"],"gpt_icon":0},{"id":"2607709387","title":"康哲药业01月28日主力净流入151.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2607709387","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607709387?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:16","pubTimestamp":1769588160,"startTime":"0","endTime":"0","summary":"01月28日, 康哲药业股价涨1.01%，报收13.94元，成交金额5155.3万元，换手率0.15%，振幅1.81%，量比1.26。康哲药业今日主力资金净流入151.2万元，上一交易日主力净流出125.2万元。该股近5个交易日上涨0.36%，主力资金累计净流入714.1万元，其中3个交易日为股价下跌时净流入；近20日主力资金累计净流入1455.9万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128162725a6b671ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128162725a6b671ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BYV24P56.USD","00867","IE00BVYPNQ40.USD","IE00BMCWC346.EUR","SG9999015952.SGD","SG9999015978.USD","IE00BGHQDM52.EUR","SG9999004220.SGD","SG9999015945.SGD","BK1191","SG9999015986.USD","LU2488822045.USD","IE00BVYPNP33.GBP","BK1593"],"gpt_icon":0},{"id":"2606207393","title":"每日卖空追踪 | 康哲药业 01月27日卖空量成交7万股，卖空比例为2.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606207393","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606207393?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:30","pubTimestamp":1769502617,"startTime":"0","endTime":"0","summary":"康哲药业北京时间01月27日，涨0.58%，卖空量成交7万股，较上一交易日减少43.09%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127163700a45b3aad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127163700a45b3aad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015945.SGD","SG9999015986.USD","00867","IE00BMCWC346.EUR","BK1593","SG9999015952.SGD","IE00BYV24P56.USD","SG9999015978.USD","LU2488822045.USD","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","SG9999004220.SGD","IE00BVYPNP33.GBP","BK1191"],"gpt_icon":0},{"id":"2605545126","title":"招商证券：首予康哲药业(00867)“强烈推荐”评级 创新化+国际化助力商业化龙头迈入新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2605545126","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605545126?lang=zh_cn&edition=full","pubTime":"2026-01-21 09:37","pubTimestamp":1768959456,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券发布研报称，首次覆盖，给予康哲药业“强烈推荐”评级，该行认为集采对公司业绩影响基本出清，公司通过“海外授权+国内合作+自主研发”构建了丰富的创新药管线，2024年起多个重磅产品商业化驱动业绩拐点，将进入创新药和国际化驱动增长的新阶段。截至2025H1在东南亚、中东及港澳台市场累计提交近20款药品和医疗器械上市申请，覆盖皮肤科、眼科、肿瘤和免疫等领域，实现芦可替尼乳膏等产品在港澳等区域商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00867","06099"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cms.net.cn","stockEarnings":[{"period":"1week","weight":0.0459},{"period":"1month","weight":0.0744},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1109},{"period":"1year","weight":1.1006},{"period":"ytd","weight":0.1302}],"compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0136},{"period":"6month","weight":0.08},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康哲药业控股有限公司是一家主要从事药品生产、营销、推广及销售业务的投资控股公司。该公司的产品包括波依定、优思弗、施图伦滴眼液、喜辽妥、艾蓓尔产品系列及Vmonalisa莫娜丽莎等。其主要在售产品覆盖心脑血管、消化、眼科、皮肤科及医美领域。该公司主要在中国国内和海外市场销售其产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.010984},{"month":2,"riseRate":0.6,"avgChangeRate":0.034568},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.002353},{"month":4,"riseRate":0.533333,"avgChangeRate":0.029521},{"month":5,"riseRate":0.466667,"avgChangeRate":0.01146},{"month":6,"riseRate":0.666667,"avgChangeRate":0.005887},{"month":7,"riseRate":0.533333,"avgChangeRate":-0.008683},{"month":8,"riseRate":0.4,"avgChangeRate":0.021846},{"month":9,"riseRate":0.466667,"avgChangeRate":0.00566},{"month":10,"riseRate":0.5,"avgChangeRate":0.008421},{"month":11,"riseRate":0.5625,"avgChangeRate":0.054281},{"month":12,"riseRate":0.5625,"avgChangeRate":0.03433}],"exchange":"SEHK","name":"康哲药业","nameEN":"CMS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康哲药业,00867,康哲药业股票,康哲药业股票老虎,康哲药业股票老虎国际,康哲药业行情,康哲药业股票行情,康哲药业股价,康哲药业股市,康哲药业股票价格,康哲药业股票交易,康哲药业股票购买,康哲药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}